Department of Pharmacology and Toxicology, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia.
Drug Des Devel Ther. 2023 Mar 21;17:851-861. doi: 10.2147/DDDT.S402362. eCollection 2023.
Tapentadol is an analgesic compound that acts centrally to attenuate pain. Previous studies have shown that tapentadol has dual mechanisms of action as a mu-opioid receptor agonist and noradrenaline re-uptake inhibition. Therefore, tapentadol provides a great advantage over classic opioids in pain management from nociceptive to neuropathic. Cumulative evidence from in vitro data suggests that tapentadol effect of norepinephrine re-uptake could be a new target that overcomes other classic opioids in chronic neuropathic pain. Compared to tramadol and other opioids, tapentadol is associated with fewer adverse effects than tramadol. Tapentadol is a new alternative to treat acute, chronic, and neuropathic pain. Thus, this review article was focused on understanding the studies that led to the development of tapentadol as a novel analgesic drug and its advantages over conventional opioids. Thus, tapentadol is a good alternative with fewer adverse effects and is available for human use.
曲马多是一种中枢性镇痛药，通过作用于μ-阿片受体和抑制去甲肾上腺素再摄取而发挥双重镇痛作用。因此，曲马多在治疗从伤害感受性疼痛到神经病理性疼痛方面优于经典阿片类药物。体外数据的累积证据表明，曲马多对去甲肾上腺素再摄取的作用可能是一种新的靶点，可以克服慢性神经病理性疼痛中的其他经典阿片类药物。与曲马多和其他阿片类药物相比，曲马多的不良反应少于曲马多。曲马多是治疗急性、慢性和神经病理性疼痛的新选择。因此，本文综述了曲马多作为一种新型镇痛药的研发历程及其相对于传统阿片类药物的优势。因此，曲马多是一种不良反应较少且可供人类使用的良好替代品。
